IN2012DN02982A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02982A IN2012DN02982A IN2982DEN2012A IN2012DN02982A IN 2012DN02982 A IN2012DN02982 A IN 2012DN02982A IN 2982DEN2012 A IN2982DEN2012 A IN 2982DEN2012A IN 2012DN02982 A IN2012DN02982 A IN 2012DN02982A
- Authority
- IN
- India
- Prior art keywords
- 6alkyl
- group
- 20alkyl
- halo
- alkyl
- Prior art date
Links
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 1
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 206010011416 Croup infectious Diseases 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- DZFLWZSJWNYVEU-UHFFFAOYSA-N P(O)(O)(O)=O.[PH2](=O)O Chemical compound P(O)(O)(O)=O.[PH2](=O)O DZFLWZSJWNYVEU-UHFFFAOYSA-N 0.000 abstract 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 1
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010549 croup Diseases 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24833809P | 2009-10-02 | 2009-10-02 | |
| PCT/EP2010/064687 WO2011039365A1 (en) | 2009-10-02 | 2010-10-01 | Anti inflammatory 2-oxothiazoles and 2 -oxooxazoles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN02982A true IN2012DN02982A (enrdf_load_stackoverflow) | 2015-07-31 |
Family
ID=43221889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2982DEN2012 IN2012DN02982A (enrdf_load_stackoverflow) | 2009-10-02 | 2010-10-01 |
Country Status (11)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2012DN02982A (enrdf_load_stackoverflow) | 2009-10-02 | 2015-07-31 | Avexxin As | |
| GB201205394D0 (en) | 2012-03-27 | 2012-05-09 | Adlens Ltd | Improvements in or relating to deformable non-round membrane assemblies |
| GB201221329D0 (en) | 2012-11-27 | 2013-01-09 | Avexxin As | Dermatitis treatment |
| JP6371312B2 (ja) | 2013-01-29 | 2018-08-08 | アヴェクシン エーエス | 坑炎症および抗腫瘍２−オキソチアゾール化合物ならびに２−オキソチオフェン化合物 |
| GB201307331D0 (en) * | 2013-04-23 | 2013-05-29 | Norwegian Univ Sci & Tech Ntnu | Compound |
| GB201409363D0 (en) | 2014-05-27 | 2014-07-09 | Avexxin As | Skin cancer treatment |
| GB201413695D0 (en) | 2014-08-01 | 2014-09-17 | Avexxin As | Compound |
| GB201604316D0 (en) | 2016-03-14 | 2016-04-27 | Avexxin As | Combination therapy |
| GB201604318D0 (en) | 2016-03-14 | 2016-04-27 | Avexxin As | Combination therapy |
| GB2550363A (en) * | 2016-05-16 | 2017-11-22 | Avexxin As | Compound |
| EP3515422A1 (en) | 2016-09-21 | 2019-07-31 | Avexxin AS | Pharmaceutical composition |
| JP2019532980A (ja) * | 2016-11-04 | 2019-11-14 | アヴェクシン エーエス | 皮膚症状を治療するためのチアゾールおよび副腎皮質ステロイドを含む併用療法 |
| US20190275010A1 (en) * | 2016-11-04 | 2019-09-12 | Avexxin As | Combination therapy comprising a thiazole and a secosteroid to treat skin conditions |
| JP7169584B2 (ja) * | 2018-01-30 | 2022-11-11 | 公立大学法人横浜市立大学 | オーキシン生合成阻害活性を有する新規化合物、その製造方法及びその用途 |
| GB201806663D0 (en) | 2018-04-24 | 2018-06-06 | Avexxin As | 2-Oxothiazole compositions for treatment of fibrotic disease |
| EP3677259A1 (en) * | 2019-01-07 | 2020-07-08 | Mosaiques Diagnostics And Therapeutics AG | Use of arachidonyl trifluoromethyl ketone |
| GB202117609D0 (en) | 2021-12-06 | 2022-01-19 | Coegin Pharma Ab | 2-Oxothiazole compositions for treatment of T-cell acute lymphoblastic leukaemia |
| CN115028597B (zh) * | 2022-04-29 | 2024-03-26 | 闽都创新实验室 | 一种tempo连续脱氢环化制备苯并恶唑类衍生物的方法和应用 |
| WO2025125241A1 (en) | 2023-12-15 | 2025-06-19 | Coegin Pharma Ab | Pharmaceutical composition |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2062868B1 (enrdf_load_stackoverflow) | 1969-09-15 | 1973-08-10 | Innothera Lab Sa | |
| US3894152A (en) * | 1969-09-15 | 1975-07-08 | Innothera Lab Sa | Use of (thienyl-3)(3-N-morpholine-propy)ketone |
| DE2063901A1 (en) | 1970-12-28 | 1972-07-20 | Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt | Phenylalkylaminoalkylthiazoles - as antiphlogistics |
| US5177215A (en) | 1984-11-12 | 1993-01-05 | Yamanouchi Pharmaceutical Co., Ltd. | Heterocyclic compounds and pharmaceutical use thereof |
| PH22520A (en) | 1984-11-12 | 1988-10-17 | Yamanouchi Pharma Co Ltd | Heterocyclic compounds having 4-lover alkyl-3-hydroxy-2-lower alkyl phenoxy-lower alkylene-y-group, and process of producing them |
| JPS62142168A (ja) | 1985-10-16 | 1987-06-25 | Mitsubishi Chem Ind Ltd | チアゾ−ル誘導体及びそれを有効成分とするロイコトリエンきつ抗剤 |
| ZA894913B (en) | 1988-07-12 | 1990-03-28 | Ici Pharma | Heterocyclic compounds |
| US5272986A (en) | 1991-05-13 | 1993-12-28 | British Gas Plc | Towing swivel for pipe inspection or other vehicle |
| TW263504B (enrdf_load_stackoverflow) | 1991-10-03 | 1995-11-21 | Pfizer | |
| GB9211706D0 (en) | 1992-06-03 | 1992-07-15 | Celltech Ltd | Peptidyl derivatives |
| US5273986A (en) | 1992-07-02 | 1993-12-28 | Hoffmann-La Roche Inc. | Cycloalkylthiazoles |
| US5268395A (en) | 1992-10-13 | 1993-12-07 | Martin Marietta Energy Systems, Inc. | Microcellular carbon foam and method |
| JP3345476B2 (ja) * | 1993-05-18 | 2002-11-18 | 株式会社東芝 | 有機非線形光学材料 |
| US5569655A (en) * | 1993-09-14 | 1996-10-29 | Sterling Winthrop Inc. | Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof |
| WO1996003392A1 (en) | 1994-07-27 | 1996-02-08 | G.D. Searle & Co. | Substituted thiazoles for the treatment of inflammation |
| US6214994B1 (en) * | 1997-04-21 | 2001-04-10 | Molecular Geriatrics Corporation | Certain substituted 1-aryl-3-piperazin-1′-yl propanones |
| US5693804A (en) * | 1994-11-17 | 1997-12-02 | Molecular Geriatrics Corporation | Substituted 1-aryl-3-piperazin-1'-yl propanones |
| US5658909A (en) * | 1994-11-17 | 1997-08-19 | Molecular Geriatrics Corporation | Certain substituted 1-aryl-3-piperazin-1'-yl propanones to treat Alzheimer's Disease |
| US5900426A (en) | 1995-03-28 | 1999-05-04 | Nippon Zoki Pharmaceutical Co., Ltd. | Benzothiazole derivatives |
| WO1996036617A1 (en) * | 1995-05-19 | 1996-11-21 | G.D. Searle & Co. | Substituted oxazoles for the treatment of inflammation |
| CA2224121A1 (en) * | 1995-06-06 | 1996-12-12 | Donna Kaye Wilson | Stereoselective method for synthesizing dolaphenine |
| DE19638408A1 (de) * | 1996-09-19 | 1998-03-26 | Merckle Gmbh | 1-Substituierte 3-Acyl-4,5-dimethylpyrrol-2-carbonsäuren und 3-Acylindol-2-carbonsäuren sowie ihre Derivate als Hemmstoffe der cytosolischen Phospholipase A¶2¶ |
| US6414145B1 (en) * | 1997-01-29 | 2002-07-02 | Zeneca Limited | Imidazolyl compounds as inhibitors of farnesyl-protein tranferase |
| EP0867437B1 (en) | 1997-03-14 | 2002-11-13 | Koninklijke Philips Electronics N.V. | "Method of preparing a thiophene-containing or furan -containing conjugated compound and precursor compound used therein". |
| CA2304503A1 (en) * | 1997-09-23 | 1999-04-01 | Graham Johnson | Selective cpla2 inhibitors |
| JPH11255700A (ja) | 1998-03-12 | 1999-09-21 | Taiho Ind Co Ltd | アセチルアセトン系金属錯体及びその合成法、並びにそれを用いた有機多層型エレクトロルミネッセンス素子 |
| BR9912907A (pt) | 1998-08-11 | 2001-05-08 | Bayer Agrochem Kk | Pirazóis nematicidas |
| SE9804212D0 (sv) * | 1998-12-04 | 1998-12-04 | Astra Pharma Prod | Compounds |
| EP1196384A4 (en) | 1999-06-25 | 2002-10-23 | Merck & Co Inc | 1- (AROMATIC OR HETEROAROMATICALLY SUBSTITUTED) -3- (HETEROAROMATICALLY SUBSTITUTED) -1,3-PROPANDIONS AND THEIR APPLICATIONS |
| JP2001240593A (ja) * | 1999-10-12 | 2001-09-04 | Japan Tobacco Inc | 高トリグリセリド血症治療薬及び抗肥満薬 |
| US6462054B1 (en) * | 2000-03-27 | 2002-10-08 | The Scripps Research Institute | Inhibitors of fatty acid amide hydrolase |
| MXPA02011353A (es) | 2000-05-18 | 2005-07-01 | Daiichi Seiyaku Co | Derivados novedosos de benzotiofeno. |
| US20020052373A1 (en) | 2000-10-26 | 2002-05-02 | Zorn Stevin H. | Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease |
| US6734207B2 (en) * | 2001-04-20 | 2004-05-11 | Parker Hughes Institute | Cytotoxic compounds |
| US7056917B2 (en) | 2001-04-26 | 2006-06-06 | Daiichi Pharmaceutical Co., Ltd. | Drug efflux pump inhibitor |
| AU2002351330A1 (en) | 2001-12-18 | 2003-06-30 | 3Cpm Company | Endoscopic measurement of myoelectrical activity from intra-abdominal organs |
| GB0202002D0 (en) * | 2002-01-29 | 2002-03-13 | Leiv Eiriksson Nyotek A S | Use |
| BR0312957A (pt) | 2002-07-27 | 2005-06-14 | Astrazeneca Ab | Composto ou um sal farmaceuticamente aceitável deste, uso do mesmo, composição farmacêutica, e, método para produzir um efeito inibidor de 11betahsd1 em um animal de sangue quente, tal como o homem, em necessidade de tal tratamento |
| SE0202463D0 (sv) * | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel compounds |
| US6930391B2 (en) | 2002-08-27 | 2005-08-16 | Intel Corporation | Method for alloy-electroplating group IB metals with refractory metals for interconnections |
| EP2093220A3 (en) | 2002-10-08 | 2009-11-11 | The Scripps Research Institute | Inhibitors of fatty acid amide hydrolase |
| GB2394894B (en) | 2002-11-04 | 2005-08-31 | G W Pharma Ltd | New use for pharmaceutical composition |
| JP2006514102A (ja) * | 2002-11-07 | 2006-04-27 | アストラゼネカ アクチボラグ | ２−オキソ−エタンスルホンアミド誘導体 |
| EP1674460B1 (en) | 2003-09-18 | 2009-01-21 | Tokuyama Corporation | Chromene compound |
| TWI336697B (en) * | 2003-09-19 | 2011-02-01 | Solvay Pharm Bv | Thiazole derivatives as cannabinoid receptor modulators |
| JP4226438B2 (ja) | 2003-10-23 | 2009-02-18 | エヌ・ティ・ティ・コムウェア株式会社 | パック装置およびセンステーブル装置、ならびに移動軌跡算出方法、移動軌跡算出プログラム、その記録媒体 |
| US20050137243A1 (en) | 2003-12-23 | 2005-06-23 | Souers Andrew J. | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor |
| JP2005343889A (ja) * | 2004-05-06 | 2005-12-15 | Taisho Pharmaceut Co Ltd | イミダゾピリジン誘導体 |
| CN1953968B (zh) * | 2004-05-17 | 2012-10-10 | 大塚制药株式会社 | 噻唑化合物及其用途 |
| US7178364B2 (en) | 2004-07-22 | 2007-02-20 | Shapiro Kristen M | Personal adornment |
| WO2006016218A1 (en) * | 2004-08-03 | 2006-02-16 | Pfizer Japan Inc. | Aryl or heteroaryl carbonyl derivatives derivatives useful as vanilloid receptor 1 (vr1) antagonists |
| WO2006057503A1 (en) * | 2004-11-25 | 2006-06-01 | Lg Life Sciences, Ltd. | NOVEL COMPOUNDS AS AGONIST FOR PPARϜ AND PPARα, METHOD FOR PREPARATION OF THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME |
| WO2007061862A2 (en) * | 2005-11-18 | 2007-05-31 | Janssen Pharmaceutica N.V. | 2-keto-oxazoles as modulators of fatty acid amide hydrolase |
| HUE030418T2 (en) * | 2005-12-13 | 2017-05-29 | Incyte Holdings Corp | Heteroaryl-substituted pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines as Janus kinase inhibitors |
| AU2007217813A1 (en) | 2006-02-17 | 2007-08-30 | The Scripps Research Institute | Oxazole ketones as modulators of fatty acid amide hydrolase |
| WO2008013963A2 (en) * | 2006-07-28 | 2008-01-31 | University Of Connecticut | Fatty acid amide hydrolase inhibitors |
| CA2678735A1 (en) * | 2007-02-26 | 2008-09-04 | Santen Pharmaceutical Co., Ltd. | Novel pyrrole derivative having ureido group and aminocarbonyl group as substituents |
| WO2008107335A1 (en) * | 2007-03-05 | 2008-09-12 | F. Hoffmann-La Roche Ag | Aminoamides as orexin antagonists |
| CA2689148A1 (en) * | 2007-05-31 | 2008-12-11 | The Scripps Research Institute | Tricyclic inhibitors of fatty acid amide hydrolase |
| IN2012DN02982A (enrdf_load_stackoverflow) | 2009-10-02 | 2015-07-31 | Avexxin As | |
| US20130231468A1 (en) | 2010-11-22 | 2013-09-05 | Takeshi Yamashita | Rare earth metal complex |
| JP6371312B2 (ja) * | 2013-01-29 | 2018-08-08 | アヴェクシン エーエス | 坑炎症および抗腫瘍２−オキソチアゾール化合物ならびに２−オキソチオフェン化合物 |
| GB201413695D0 (en) * | 2014-08-01 | 2014-09-17 | Avexxin As | Compound |
-
2010
- 2010-10-01 IN IN2982DEN2012 patent/IN2012DN02982A/en unknown
- 2010-10-01 EP EP18170271.3A patent/EP3431084A1/en not_active Withdrawn
- 2010-10-01 KR KR1020197018997A patent/KR20190082985A/ko not_active Withdrawn
- 2010-10-01 DK DK10759934.2T patent/DK2482815T3/en active
- 2010-10-01 KR KR1020187028820A patent/KR101997163B1/ko not_active Expired - Fee Related
- 2010-10-01 WO PCT/EP2010/064687 patent/WO2011039365A1/en active Application Filing
- 2010-10-01 CN CN201310675185.1A patent/CN103772312B/zh active Active
- 2010-10-01 KR KR1020177008521A patent/KR101907535B1/ko not_active Expired - Fee Related
- 2010-10-01 NO NO10759934A patent/NO2482815T3/no unknown
- 2010-10-01 CA CA2782797A patent/CA2782797C/en active Active
- 2010-10-01 JP JP2012531448A patent/JP6012468B2/ja not_active Expired - Fee Related
- 2010-10-01 CN CN201080056033.8A patent/CN102647984B/zh active Active
- 2010-10-01 AU AU2010302584A patent/AU2010302584B2/en not_active Ceased
- 2010-10-01 KR KR1020127011173A patent/KR20120089701A/ko not_active Ceased
- 2010-10-01 EP EP10759934.2A patent/EP2482815B1/en not_active Not-in-force
- 2010-10-01 CN CN201510086534.5A patent/CN104892542B/zh active Active
- 2010-10-04 US US12/897,510 patent/US9597318B2/en not_active Expired - Fee Related
-
2017
- 2017-02-24 US US15/442,568 patent/US10370344B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2782797A1 (en) | 2011-04-07 |
| CN102647984A (zh) | 2012-08-22 |
| EP2482815A1 (en) | 2012-08-08 |
| AU2010302584B2 (en) | 2015-09-10 |
| KR101907535B1 (ko) | 2018-10-15 |
| JP2013506639A (ja) | 2013-02-28 |
| HK1210157A1 (en) | 2016-04-15 |
| JP6012468B2 (ja) | 2016-10-25 |
| DK2482815T3 (en) | 2018-06-06 |
| WO2011039365A1 (en) | 2011-04-07 |
| KR20190082985A (ko) | 2019-07-10 |
| AU2010302584A1 (en) | 2012-05-24 |
| KR20120089701A (ko) | 2012-08-13 |
| US9597318B2 (en) | 2017-03-21 |
| CN103772312A (zh) | 2014-05-07 |
| US10370344B2 (en) | 2019-08-06 |
| EP3431084A1 (en) | 2019-01-23 |
| EP2482815B1 (en) | 2018-05-02 |
| CA2782797C (en) | 2018-08-07 |
| NO2482815T3 (enrdf_load_stackoverflow) | 2018-09-29 |
| CN104892542B (zh) | 2018-01-26 |
| CN102647984B (zh) | 2015-03-25 |
| US20170166539A1 (en) | 2017-06-15 |
| KR20180114228A (ko) | 2018-10-17 |
| HK1197551A1 (zh) | 2015-01-23 |
| KR20170038941A (ko) | 2017-04-07 |
| KR101997163B1 (ko) | 2019-07-08 |
| US20110136879A1 (en) | 2011-06-09 |
| CN104892542A (zh) | 2015-09-09 |
| CN103772312B (zh) | 2016-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN02982A (enrdf_load_stackoverflow) | ||
| AR117799A2 (es) | Sal(es) de dimetil-amida del ácido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]-pirimidin-6-carboxílico y procesos para su elaboración | |
| AR116395A2 (es) | 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida, su monohidrato o sal en una forma de pureza alta | |
| DK2078026T3 (da) | Prodrug-salte af 2, 4-pyrimidinediamine-forbindelser og anvendelser deraf | |
| MX2017014714A (es) | Derivados de benzoimidazol como inhibidores de peptidil arginina deiminasa 4 (pad4). | |
| NZ599797A (en) | Isoxazoline compositions and their use as antiparasitics | |
| EA201791584A1 (ru) | Агрохимическая композиция | |
| DOP2017000213A (es) | Derivados de bencimidazol como inhibidores de bromodominio | |
| MX351581B (es) | Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen. | |
| EA201790810A1 (ru) | Активная композиция для мягчителя ткани | |
| NO20080129L (no) | Fremgangsmate for fremstilling av dihydrokinazoliner | |
| EA201300282A1 (ru) | Производные триазолопиразина | |
| NZ701894A (en) | Dimethyl-benzoic acid compounds | |
| MX2015014336A (es) | Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida. | |
| UA117673C2 (uk) | Поліміксини, композиція, спосіб одержання і спосіб застосування (варіанти) | |
| BR112013030051A2 (pt) | método de tratar artigos com dióxido de carbono | |
| PH12015502429A1 (en) | Dicarboxylic acid compound | |
| EA201400210A1 (ru) | Применение и агрохимическая композиция дибутиламидов карбоновой кислоты | |
| MX2016003441A (es) | Metodos para producir acidos poliasparticos. | |
| MX348979B (es) | Agente de control de enfermedades de las plantas. | |
| MX381478B (es) | Composicion dispersante liquida para yeso. | |
| UA115072C2 (uk) | Похідні гідантоїну | |
| MX2013003581A (es) | Proceso para producir granulos que comprende una o mas sales de agentes complejas. | |
| GB201308503D0 (en) | Novel microbiocides | |
| TN2014000329A1 (en) | Method for preparing compound by novel michael addition reaction using water or various acids as additive |